Baudax Bio Announces U.S. Availability of ANJESO™ (meloxicam) Injection for the Management of Moderate to Severe Pain

Apr 07, 2020 8:00am EDT

Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 03, 2020 6:40pm EDT

Baudax Bio Announces Closing of $25 Million Public Offering of Securities

Mar 26, 2020 11:35am EDT

Baudax Bio Announces Pricing of Public Offering of Common Stock and Warrants

Mar 24, 2020 9:15am EDT

Baudax Bio Announces Proposed Public Offering of Common Stock and Warrants

Mar 23, 2020 4:20pm EDT

Baudax Bio Signs Non-Binding Term Sheet for Debt Facility

Mar 04, 2020 11:42am EST

Baudax Bio Announces FDA Approval of ANJESO™ for the Management of Moderate to Severe Pain

Feb 20, 2020 4:05pm EST

Baudax Bio Reports 2019 Annual Financial Results

Feb 13, 2020 4:08pm EST

Baudax Bio Announces PDUFA Date for Intravenous Meloxicam

Jan 22, 2020 7:00am EST

Baudax Bio to Present at the Piper Jaffray 31st Annual Healthcare Conference

Dec 03, 2019 7:00am EST